Key facts
- This page summarizes Amit B. Shah's Form 4 filing for Oncotelic Therapeutics, Inc. (OTLC).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jul 2021, 17:37.
Amit B. Shah - 08 Jul 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)
- Reporting relationship
- CHIEF FINANCIAL OFFICER
- Issuer ticker
- OTLC
- Reported as of
- 08 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2021, 17:37:37 UTC
- Next SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amit Shah
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Amit B. Shah filed Form 4 for Oncotelic Therapeutics, Inc. (OTLC) on 16 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OTLC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +298,837
- Change %
- +498%
- Price
- $0.000000
- Shares after
- 358,837
- Date
- 08 Jul 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OTLC
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +698,256
- Change %
- Price
- $0.000000
- Shares after
- 698,256
- Date
- 08 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 698,256
- Exercise price
- $0.1626
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.
Footnote F2
Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on date of grant.